DEA Schedules Remimazolam, Used in Induction and Maintenance of Procedural Sedation in Adults
October 14, 2020 at 14:57:18 ET
In an order issued Oct. 6, the DEA placed in Schedule IV a newly approved drug intended for the treatment of patients undergoing medical procedures lasting 30 minutes or less (85 Fed. Reg. 63014, Oct. 6, 2020).
Cosmo Technologies Inc. filed a new drug application (NDA) for remimazolam with the FDA, and the NDA was approved on July 2, 2020. The drug is marketed under the brand name ... Read More
